Not yet recruiting
Erysipelas
Not yet recruitingA study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.
Registered drugNo placebo
A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.
Registered drugNo placebo
- Disease:Erysipelas
- Substances:Dalbavancin
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Dalbavancin
- Sponsor:Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

